aTyr Pharma (ATYR) Q4 2025 earnings summary

Executive summary

• Reported results for Q4 and full year 2025, highlighting progress in clinical programs for efzofitimod in pulmonary sarcoidosis and systemic sclerosis-related ILD.

• Scheduled FDA Type C meeting in April 2026 to discuss Phase 3 EFZO-FIT study results and next steps for efzofitimod.

• Phase 2 EFZO-CONNECT study enrollment on track for completion in H1 2026.

Financial highlights

• Ended 2025 with $80.9 million in cash, cash equivalents, restricted cash, and investments.

• Research and development expenses were $60.2 million for 2025, primarily for clinical studies and preclinical candidates.

• General and administrative expenses totaled $17.6 million for 2025.

• Net loss for 2025 was $74.1 million, compared to $64.0 million in 2024.

• Net loss per share for 2025 was $0.80, compared to $0.86 in 2024.

Outlook and guidance

• Plans to provide an update on efzofitimod's regulatory path after the FDA meeting in April 2026.

• Expects Phase 2 EFZO-CONNECT study to complete enrollment in the first half of 2026.